Fundraising FoxTherakos
1 known investors
Find your way into Therakos
Sign up to see every warm intro you have to Therakos
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Therakos team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Therakos develops THERAKOS Photopheresis, an FDA-approved extracorporeal photopheresis (ECP) system used to treat skin symptoms of cutaneous T-cell lymphoma (CTCL) unresponsive to other treatments. It provides medical devices and associated drug therapy for clinicians treating CTCL patients.
Investors · 1
Frequently asked questions
- What does Therakos do?
- Therakos develops THERAKOS Photopheresis, an FDA-approved extracorporeal photopheresis (ECP) system used to treat skin symptoms of cutaneous T-cell lymphoma (CTCL) unresponsive to other treatments. It provides medical devices and associated drug therapy for clinicians treating CTCL patients.
- Who are Therakos's investors?
- Therakos's investors include Gores.